Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

BACKGROUND: The combination of chemotherapy with the vascular endothelial growth factor (VEGF) antibody bevacizumab is a standard of care in advanced colorectal cancer (CRC). However, biomarkers predicting outcome of bevacizumab-containing treatment are lacking. As angiopoietin-2 (Ang-2) is a key re...

Descripción completa

Detalles Bibliográficos
Autores principales: Goede, V, Coutelle, O, Neuneier, J, Reinacher-Schick, A, Schnell, R, Koslowsky, T C, Weihrauch, M R, Cremer, B, Kashkar, H, Odenthal, M, Augustin, H G, Schmiegel, W, Hallek, M, Hacker, U T
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990609/
https://www.ncbi.nlm.nih.gov/pubmed/20924372
http://dx.doi.org/10.1038/sj.bjc.6605925

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2990609/
https://www.ncbi.nlm.nih.gov/pubmed/20924372
http://dx.doi.org/10.1038/sj.bjc.6605925

Ejemplares similares